No phaseStatus unknown
A Proof-of-concept Single-arm clinical trial Of semaglutide after withdrawal of biologic therapy for chronic plaque psoriasis in people with overweight/obesity (PSO-withdraw)
A Proof-of-concept Single-arm clinical trial Of semaglutide after withdrawal of biologic therapy for control of chronic plaque psoriasis in people with overweight/obesity (PSO-withdraw)
- Sponsor
- Bayside Health
- Enrolment
- 25 planned
- Conditions
- psoriasis; obesity; chronic plaque psoriasis; psoriasis obesity chronic plaque psoriasis; Diet and Nutrition - Obesity; Skin - Dermatological conditions; Inflammatory and Immune System - Autoimmune diseases
- Interventions
- In this study, semaglutide will be given upon stopping biologic therapy to see if it helps maintain psoriasis control
- Ages
- adults, older adults
- Registry
- ACTRN12626000951358
Full record on ANZCTRSource: WHO ICTRP, processed 24 August 2026
Primary outcomes
- To determine whether initiation of semaglutide at the time of biologic therapy discontinuation maintains psoriasis disease control in adults with chronic plaque psoriasis and overweight/obesity. [PASI, Phyisican Global Assessment of Psoriasis (PGA-Pso) 12 months post discontinuation of biologic ther
History
Last registry update
Registered
Started